HealthlineCommon Rheumatoid Arthritis Drug May Support Hair Regrowth in Alopecia

Nearly 1,400 participants aged 12 to 64 received upadacitinib 15 mg, 30 mg, or placebo. All participants had alopecia areata affecting at least half their scalp.

Clinical Considerations

• Nearly half receiving 15 mg and over 54% receiving 30 mg achieved at least 80% scalp coverage.
• Complete scalp regrowth occurred in 13% and 23% of the respective treatment groups.
• Acne, upper respiratory infections, colds, and throat irritation represented the most frequently reported adverse events.
• The initial comparison covered 24 weeks, leaving treatment durability and long-term risk-benefit balance unresolved.

Practice Applications

• Recognize upadacitinib as an investigational alopecia option, not an approved indication.
• Interpret dose-response findings alongside systemic JAK inhibitor safety considerations.
• Consider adolescents within the studied population when evaluating future evidence.
• Monitor regulatory decisions and longer-term efficacy and safety results.